Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R9EQ
|
|||
| Former ID |
DAP000068
|
|||
| Drug Name |
Ropinirole
|
|||
| Synonyms |
Ropinirol; Ropinirolum; Ropitor; ReQuip CR; ReQuip XL; SKF 101468; Adartrel (TN); Requip (TN); Ropark (TN); Ropinirol[INN-Spanish]; Ropinirole (INN); Ropinirole [INN:BAN]; Ropinirolum [INN-Latin]; Ropitor (TN); SK&F 101468; SK&F-101,468; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Approved | [1], [2] | |
| Therapeutic Class |
Antiparkinson Agents
|
|||
| Company |
GlaxoSmithKline plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H24N2O
|
|||
| Canonical SMILES |
CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
|
|||
| InChI |
1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
|
|||
| InChIKey |
UHSKFQJFRQCDBE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 91374-21-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9767, 5146352, 7980537, 8153134, 11111741, 15221518, 26612814, 26750081, 29224163, 46507918, 47736591, 49835672, 49984920, 50107804, 50424103, 56394866, 57322604, 85174439, 85209268, 85787467, 90341563, 92308034, 92729677, 93166984, 96025175, 99213707, 103181541, 103931441, 104171231, 104308262, 118043478, 124750235, 124881334, 125359636, 126534096, 126651383, 126670701, 129370011, 134337396, 134338699, 134340280, 135049181, 137001317, 139157655, 144075778, 144203807, 151982542, 152159669, 160963616, 163109193
|
|||
| ChEBI ID |
CHEBI:8888
|
|||
| ADReCS Drug ID | BADD_D01966 ; BADD_D01967 | |||
| SuperDrug ATC ID |
N04BC04
|
|||
| SuperDrug CAS ID |
cas=091374219
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D2 receptor (D2R) | Target Info | Modulator | [3] |
| Dopamine D3 receptor (D3R) | Target Info | Modulator | [3] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| Rap1 signaling pathway | ||||
| cAMP signaling pathway | ||||
| Gap junction | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Nicotine pharmacodynamics pathway | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| Hypothetical Network for Drug Addiction | ||||
| Genes and (Common) Pathways Underlying Drug Addiction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7295). | |||
| REF 2 | Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:33-6. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.